# A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

> **NCT02653443** · PHASE2 · TERMINATED · sponsor: **Cerus Corporation** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.
- **BIOLOGICAL:** Autologous apheresis Conventional untreated Platelet Components

## Key facts

- **NCT ID:** NCT02653443
- **Lead sponsor:** Cerus Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02653443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02653443, "A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02653443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*